Met Life Investment Management, LLC Phathom Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 25,845 shares of PHAT stock, worth $379,663. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,845
Previous 25,845
-0.0%
Holding current value
$379,663
Previous $247,000
19.43%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding PHAT
# of Institutions
155Shares Held
65.4MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million14.46% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...